AQST שווי כולל של נכסי החברה Aquestive Therapeutics Inc

This price visualization for Aquestive Therapeutics (AQST), which assists in the asset's fundamental valuation, shows total assets at 112.90. The firm's competitiveness is growing through the development of unique sublingual epinephrine patches. US-based production relies on innovative thin films for the therapy of neurological disorders. Meanwhile, the business is supported by steady demand, although risks are associated with potential disruptions in raw material logistics from Asia.

Aquestive Therapeutics (AQST) relies on proprietary drug delivery technologies that require capital-intensive bioequivalence investments to protect its market niche. The total liabilities and equity, reverse-calculated via ROA, demonstrate the actual scale of resources deployed to create these barriers. By analyzing the asset trajectory through ROA, an investor assesses capital management efficiency and the balance between expansion and financial risks.